38results about How to "Improve gene transfer efficiency" patented technology

The present invention involves methods and compositions for increasing the susceptibility of target cells to transduction by gene transfer vectors. Specifically, it is proposed that increasing intracellular permeability in epithelial tissue increases the percentage of input vector that will transduce that target tissue. Specific examples show that receptors for retrovirus are preferentially accessible on the basolateral surface of airway epithelia, and permeabilizing such tissues results in greater infection with retrovirus. This has important implications in gene therapy, for example, to treat cystic fibrosis with the CFTR gene.

A gene transfer efficiency enhancer of the present invention which contains a histone deacetylase inhibitor (especially compound (A)) as an active ingredient is capable of enhancing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector while retaining the advantages of the adeno-associated virus vector.

The present invention provides a more safe and highly effective stent having functions such as anti-inflammatory action, antithrombotic action, maintenance of tissue restoration response and maintenance of endothelial regeneration. More specifically, the drug/gene eluting stent has a layer containing a gene encoding a hybrid polypeptide on the surface. The hybrid polypeptide is preferably a bound of fibronectin-derived collagen binding domain (FNCBD) polypeptide and an anti-inflammatory factor or an angiogenic factor. The uniform fine particle size capsules can directly deliver the gene encoding the hybrid polypeptide to the lesion and have benefits of reducing the given doses, and thus improving safety and efficacy and further maintaining the efficacy for a long period.

The present invention provides a kit to carry out retrovirus-mediated gene transfer into target cells. The kit contains a functional material bearing a retrovirus binding domain, another functional material bearing a target cell binding domain, an artificial substrate for incubating the retrovirus contacted with the target cells, and a target cell growth factor for pre-stimulating target cells to spur them along the cell cycle. The kit of the invention may further comprise a recombinant retroviral vector, necessary buffers, and the like.

Improved methods for transferring a gene into target cells by using a retrovirus, wherein the gene transfer efficiency is improved and the target cells are efficiently transformed by binding the retrovirus to a functional substance which is immobilized on as carrier and having an activity of binding to retroviruses followed by washing; using an antibody capable of specifically recognizing cells, laminin or mannose-rich type sugar chain as a substance having an activity of binding to the target cells; pre-treating the target cells so as to inactivate transferrin receptor, or introducing a new functional group into the functional substance.

The invention relates to the preparation technology of dendrite macromolecule gene carrier, in particular, the dendrite macromolecule whose number of active groups is three times that of the old nuclear product is synthesized by designing a new nuclear molecule. The technical scheme is to use trihydroxymethylaminomethane to form a new nuclear molecule pentaerythritol-dodecylamine with pentaerythritol-quaternary acid chloride derivatives after a simple organic reaction. Compared with the products of old nuclear generations, the surface charge density and the number of active amine end groups of the new generation of polymers synthesized by the new nuclei are three times higher, which is conducive to obtaining higher gene transfer efficiency. The surface of this kind of polymer is rich in amine groups, which can combine with negatively charged DNA to form a nano-supramolecular complex, which can be used as a gene carrier to transfer plasmid DNA into cells. Cell transfection experiments show that its efficiency is equivalent to that of commonly used liposome gene transfer reagents, but its cytotoxicity is far less than that of the latter. Good application prospects.

The invention discloses a magnetic behavior nanometer cell automatic sorting device and appliance, which is characterized by the following: supplying magnetic behavior sorting system, example transferring system and computer controlling system; setting the magnetic sorting system at least with magnet sorting solution and molecule; using to separating candidate stem cell from peripheral blood or navel cord blood; adopting micro-computer and modern controlling technology; automatic-controlling for cell sorting and washing course of the whole course. This invention can be used as cell source for cytology research, medicine screening and animal experiment.

The invention provides a gene transfer system and method for a specific poultry primordial germ cell. The gene transfer system comprises a transposase helper plasmid containing a vasa promoter with a nucleotide sequence shown in SEQ ID NO.1. The gene transfer method comprises the steps of (1) constructing the transposase helper plasmid containing the vasa promoter or containing the vasa promoter and a universal enhancer element by using a bioengineering method; (2) constructing a transposon donor plasmid containing a target gene expression box required to be transferred by using the bioengineering method; (3) extracting the plasmids, uniformly mixing the transposon donor plasmid with the transposase plasmid according to a ratio of 1 to 2, and adjusting the final concentration of a mixed plasmid to be 500 ng-1.5 mu g/mu L; and (4) wrapping the mixed plasmid obtained in the step (3) with an embedding agent and transfecting PGCs cells in early embryo blood of poultry. Through the gene transfer system and method, efficient specific integration of exogenous genes in PGCs genomes in embryos of the poultry can be realized, so that the purpose of improving preparation efficiency of transgenetic poultry is achieved.

A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

The present invention provides a gene transfer agent, a gene transfer kit, and a gene transfer method excellent in safety and transfer efficiency. Specifically, the present invention provides a gene transfer agent composition, the gene transfer agent composition including a compound represented by any one of the following formulae DL-G1 to DL-G4: DL-G1: R¹R²NX(XH₂)₂; DL-G2: R¹R²NX(X(XH₂)₂)₂; DL-G3: R¹R²NX(X(X(XH₂)₂)₂)₂; and DL-G4: R¹R²NX(X(X(X(XH₂)₂)₂)₂)₂ (X represents —CH₂CH₂CONHCH₂CH₂N—), in which: R¹ represents an unsaturated long-chain aliphatic group; and R² represents an unsaturated long-chain aliphatic group or a saturated long-chain aliphatic group in the formulae.

The invention relates to peptides and functional derivatives thereof and their use for improving transduction efficiency of viruses into target cells.

The subject invention pertains to a biodegradable matrix material which is provided in a form that can be wrapped around a body part, in combination or impregnated with an agent that can be delivered to treat a condition via the adventitial surface of a body part, the agent being in a form that can be taken up by the matrix material. These components are provided for use in the treatment of the condition, for example, by using a sealant to form a seal around the matrix material when impregnated with the agent.

An alternatively spliced form of transforming growth factor-beta2 (TGF-β2), herein denoted Δ6-TGF-β2 is disclosed. Δ6-TGF-β2 differs from TGF-β2 in the sequence of the three C-terminal exons. This novel protein is secreted, induced by cytotoxic stress in hematopoietic stem cells, and specifically blocks the enhancing effects of TGF-β2 on adult stem cells. Δ6-TGF-β2 can be used to protect stem cells from cytotoxic stress, and to enhance maintenance of these cells in vitro during retroviral transduction. In addition, Δ6-TGF-β2 can be used to slow aging and extend longevity.